The goal of this observational study is to compare the aggregation pattern of proteinopathies (alpha-synuclein, amyloid-beta, phosphorylated tau and transactive response DNA -binding protein 43 \[TDP43\]) in skin biopsies of patients with a neurodegenerative disease like Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus. The main question it aims to answer is:
* Is there a specific pattern of aggregation of proteinopathies in skin biopsies in each neurodegenerative disease in comparison to healthy control subjects?
Skin biopsies will be analyzed using immunohistochemistry and immunofluorescence for detection of alpha-synuclein, amyloid-beta, phosphorylated tau and TAR DNA binding protein 43, and the aggregation patterns will be compared between patients with a neurodegenerative disease vs patient with normal pressure hydrocephalus vs healthy control subjects.
Patients 45 years and older
Men and women
Patients diagnosed with Alzheimer's disease, frontotemporal lobe dementia, Parkinson's disease, atypical Parkinsonism, amyotrophic lateral sclerosis or normal pressure hydrocephalus
Patients that voluntarily accept to participate in the study and accept the consent form
Patients or controls that have a personal history of cerebrovascular disease, psychiatric disease, post traumatic dementia or HIV related dementia
Patients in which the diagnosis is not clear or hasn't been confirmed
Patients or controls that have a neuroinfection
Patients or controls that a diagnosed skin disease
The patients and controls that meet the eligibility criteria will be recruited from the neurology department consult from the Hospital Central Dr Ignacio Morones Prieto
Case-control
Cross-sectional
Immunohistochemistry and immunofluorescence
Diagnostic testSkin biopsies will be analyzed using immunohistochemistry and immunofluorescence to detect the presence of aggregated a-synuclein, amyloid-b, p-TAU and TDP-43.
Aggregation pattern of a-synuclein, amyloid-b, p-TAU and TDP-43
The detection of each proteinopathy will be compared between each of them in every patient and compared to healthy control subjects.
Click on the lead sponsor to view all of their trials.
Universidad Autonoma de San Luis Potosí
Lead sponsor
Hospital Central "Dr. Ignacio Morones Prieto"
Collaborator
